Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06097-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Hongbing Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Aclarubicin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Key Research and Development Project of Department of Science and Technology, Sichuan Province, 1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University, 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Induction regimens with satisfactory remission rates are limited for patients with acute myeloid leukemia (AML) who are elderly or ineligible for intensive chemotherapy. This study is a single-arm, multicenter, prospective phase I/II study (registered with the Chinese Clinical Trial Registry as ChiCTR 2200059694 on May 8, 2022), aiming to evaluate the efficacy and safety of venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (VD-CAG) for newly diagnosed AML patients who are elderly or ineligible for intensive chemotherapy. The primary endpoint was composite complete remission (CRc) after 1 cycle of induction chemotherapy. The secondary endpoints were measurable residual disease (MRD) by flow cytometry and adverse events. Forty patients(n = 40) received 1 cycle of the VD-CAG regimen for induction chemotherapy. The median age of the patients was 64 (55-81) years, and 10 patients (25%) had secondary AML. Our results showed that 1 cycle of VD-CAG had a high overall response rate of 97.5% and CRc of 95%, and all 10 patients with secondary AML achieved CRc. Moreover, the patients who achieved CRc had deep remission, with MRD-negativity of 71.1% and 54.2% by flow cytometry and molecular assessment, respectively. In addition, blood cell recovery was quick, with a median time to absolute neutrophil count ≥ 1.0 × 109/L and platelet count ≥ 100 × 109/L at 19 days and 15.5 days, respectively. In conclusion, VD-CAG demonstrates high efficacy as an induction treatment for elderly or unfit patients with newly diagnosed AML, and it could be an alternative upfront therapy for this subpopulation, Trials with large-scale subjects are needed for further validation, especially for secondary AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
- Department of hematology, Affiliated Hospital of Chengdu University, Chengdu, China.
- Department of hematology, Dazhou Central Hospital, Dazhou, China.
- Department of hematology, The Second People's Hospital of Neijiang, Neijiang, China.
- Department of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China. gongyuping@wchscu.cn.
Förderung
- Key Research and Development Project of Department of Science and Technology, Sichuan Province
- 1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University
- 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University
Zitieren
APA
Ma, H., Du, Y., Li, J., Rao, J., Guo, Y., Yang, Y., Zhang, D., Wang, J., Liao, Y., & Gong, Y. (2024). Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-06097-w
Vancouver
Ma H, Du Y, Li J, Rao J, Guo Y, Yang Y, et al. Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-06097-w
BibTeX
@article{Ma2024,
author = {Ma, Hongbing and Du, Yiwen and Li, Jianjun and Rao, Jin and Guo, Yong and Yang, YunFan and Zhang, Duanzhong and Wang, Jia and Liao, Yi and Gong, Yuping},
title = {Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06097-w}
}
EUVIMED